Therapeutic areas with analogue competition


When several pharmaceuticals with the same clinical effect are made available on the market, analogue competition is possible. This takes place when the Danish Medicines Council prepares treatment guidelines and Amgros prepares cost analyses and conducts tendering procedures.

When the Danish Medicines Council is to assess several pharmaceuticals within the same therapeutic area, it prepares treatment guidelines. Among other things, these contain a clinical basis for comparison that describes which pharmaceuticals are clinically equal. Amgros’ job is to prepare, on behalf of the Danish Medicines Council, cost analyses for the pharmaceuticals that the Medicine Council considers equal.

Our cost analyses form the basis for a tendering procedure. On the basis of the results of this tendering procedure and the cost analyses, the Danish Medicines Council prepares a pharmaceuticals recommendation such that the pharmaceutical with the lowest total costs is ranked as first choice.

In contrast to the process for new pharmaceuticals and extensions of indication, Amgros and not the supplier completes the cost analyses. Amgros can involve suppliers during the process, and may ask for supplementary information and input on specific issues.

Read more about the assessments by the Danish Medicines Council of the therapeutic areas here.


The process

We have drawn up a figure that shows the process for therapeutic areas.

SEE FIGURE

Read more

Therapeutic areas with analogue competition

Cost analyses

When Amgros is to estimate resource consumption, we ask relevant departments and hospital pharmacies to answer specific questions in relation to the use of the equal pharmaceuticals

Read more
Therapeutic areas with analogue competition

Generic pharmaceuticals

When the patent on a pharmaceutical expires, and generic or biosimilar alternatives enter the market, Amgros’ task is to ensure the widest possible competition.

READ MORE
Therapeutic areas with analogue competition

New pharmaceuticals

If a new drug is to be considered as a standard treatment at Danish public hospitals, the Danish Medicines Council has to assess it first.

READ MORE

Sune Lindgaard

Head of Business Intelligence and Health Economy

I’m responsible for operation and development of business intelligence and health economics. I make sure that our department can proudly claim to be the partner who gets things done.